DCY636

DCY636 is an investigational therapeutic candidate being developed by Novartis for the treatment of moderate to severe atopic dermatitis. As of late 2023, it entered a first-in-human Phase 1 clinical trial (NCT06144398) designed to evaluate its safety, tolerability, and pharmacokinetics in both healthy participants and patients with atopic dermatitis. While the specific molecular target has not been widely disclosed in public pipeline summaries, the drug is part of Novartis's immunology portfolio and is being studied for its potential to modulate inflammatory pathways involved in skin disease. The Phase 1 study includes both single ascending dose (SAD) and multiple dose (MD) cohorts.